← All trials
NCT05960110
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 22, 2023
- Primary completion
- Dec 22, 2025
- Completion date
- Feb 22, 2026
- First posted
- Jul 25, 2023
- Last posted
- Jul 25, 2023
- Enrollment
- 900
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Anahuac UniversityLead sponsor
- Colgate PalmoliveCollaborator
- Anahuac UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.